NCT03740334 - Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

March 4, 2023

Study Completion Date

October 1, 2025

Conditions

Acute Lymphoblastic Leukemia ALL

Interventions

DRUG

Ribociclib

Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)

DRUG

Dexamethasone

Corticosteroids are commonly used to treat ALL.

DRUG

Everolimus

Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation

Trial Locations (12)

Memorial Sloan Kettering Cancer Center, New York

Roswell Park Cancer Institute, Buffalo

Children's Hospital of Philadelphia, Philadelphia

Nemours/Alfred I. duPont Hospital for Children, Wilmington

Children's Healthcare of Atlanta, Atlanta

Cincinnati Children's Hospital Medical Center, Cincinnati

Children's Hospital of Wisconsin, Milwaukee

Texas Children's Hospital, Houston

Children's Hospital Colorado, Aurora

Boston Children's Hospital, Boston

Dana Farber Cancer Institute, Boston

Dana-Farber Cancer Institute, Boston